Positive IDX184 clinical hold update lifts Idenix
This article was originally published in Scrip
Executive Summary
Idenix Pharmaceuticals updated investors on the status of the Cambridge, Massachusetts-based company's nucleotide polymerase inhibitor to treat hepatitis C virus (HCV) after the market closed on 1 November and said it intended to respond to the US FDA's clinical holds on IDX184 by the end of 2012.